Loop Diuretics
High-yield Verified · Oct 2026Reach the lumen by organic-anion secretion, then occupy the chloride site of NKCC2 in the thick ascending limb — the high-capacity segment — wiping out the medullary concentrating gradient and the lumen-positive voltage that drives Ca²⁺ and Mg²⁺ reabsorption.
Nursing view → administration, monitoring and patient teaching
Compare: Antihypertensives compared — mechanism and drug choice →
Drugs
Mechanism
Loop diuretics act at the thick ascending limb of the loop of Henle, inhibiting the Na-K-2Cl (NKCC2) cotransporter and blocking reabsorption of sodium, potassium, and chloride. Because this segment reclaims ~25% of filtered sodium and builds the medullary concentrating gradient, blockade produces a large natriuresis plus free-water loss — the most potent ("high-ceiling") diuresis — and it remains effective even at low GFR.
The nephron, segment by segment
The proximal tubule reclaims about 60–70% of the filtered load isotonically — sodium enters in exchange for H⁺ through NHE3, and carbonic anhydrase helps recover about 80% of filtered bicarbonate.
The thick ascending limb (TAL) reabsorbs 25–30% of filtered sodium through the apical Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2), powered by the low intracellular sodium that the basolateral Na⁺-K⁺-ATPase maintains. ROMK channels recycle potassium back into the lumen, which makes the lumen positive and pushes Na⁺, Ca²⁺ and Mg²⁺ between the cells (paracellularly) into the interstitium. The TAL has no aquaporins, so it reabsorbs solute without water — the "diluting segment" — and, through the countercurrent multiplier, builds a medullary gradient that can reach about 1200 mOsm/kg.
Downstream, the distal convoluted tubule reclaims 5–10% through NCC, the target of thiazides (see the thiazide page), and ENaC in the aldosterone-sensitive collecting duct fine-tunes about 3% (the potassium-sparing page). Loops are the most potent diuretics because they block the largest share — the reason for the "high-ceiling" label.
Blocking NKCC2 in the thick ascending limb
Loop diuretics are anions that compete with chloride for the chloride-binding site of NKCC2 on the apical membrane. Because they are highly albumin-bound they are barely filtered: they reach the lumen by active secretion through organic anion transporters in the proximal tubule, and that secretion is a prerequisite for their action.
With NKCC2 blocked, Na⁺, K⁺ and Cl⁻ stay in the lumen. The interstitium loses its tonicity, so the countercurrent concentrating mechanism fails and free water is lost; at the same time the TAL cannot dilute the tubular fluid, so excess sodium flows on to the distal nephron. ROMK recycling stalls, the lumen loses its positive charge, and the paracellular drive for Ca²⁺ and Mg²⁺ reabsorption disappears — hence calciuria.
Macula densa cells also carry NKCC2. Blocking it blunts their salt sensing, so tubuloglomerular feedback — which would otherwise constrict the afferent arteriole and lower GFR — is switched off, while low sensed salt and volume depletion release renin. The furosemide label notes that its distal action is independent of carbonic anhydrase and aldosterone, and bumetanide also has a probable proximal action (it causes phosphaturia).
Downstream: potassium, acid–base and sodium
More sodium arriving distally, plus volume depletion, activates the RAAS. Aldosterone drives avid distal sodium reabsorption, leaving the lumen negative and trapping K⁺ and H⁺ in it: hypokalemia with metabolic alkalosis, the same pattern as primary aldosteronism and more common with loops than with thiazides. Losing large volumes of sodium-rich, bicarbonate-poor fluid adds a contraction alkalosis.
Paradoxically, loops cause hyponatremia less often than thiazides: by abolishing the concentrating gradient they do not leave the kidney able to retain free water the way thiazides do. Inherited loss of NKCC2 function — type I Bartter syndrome — reproduces the loop picture from birth: hypokalemic metabolic alkalosis, hypomagnesemia and nephrocalcinosis. Cohort data, though, link hypomagnesemia more to thiazides than to loops.
Getting enough drug to the target: threshold, braking and resistance
Loops are threshold drugs: below a threshold concentration in the lumen there is no diuresis at all. Anything that cuts delivery to the lumen raises the dose needed. In CKD and decompensated heart failure less drug is secreted into the tubule, shifting the dose–response curve rightward and downward. In nephrotic syndrome, hypoproteinemia weakens furosemide’s effect and potentiates its ototoxicity. NSAIDs such as indomethacin blunt natriuresis by inhibiting prostaglandin synthesis.
The kidney also fights back. After a dose, distal tubules reabsorb sodium more avidly — the braking phenomenon — and short-acting loops leave a period of post-diuretic sodium retention as the effect wears off. Chronically, distal tubular structural adaptation adds to the resistance. Resistance can be overcome by sequential nephron blockade, adding a thiazide-like diuretic to block the adapted distal segment, or by adding acetazolamide to blunt proximal reabsorption.
Comparing the drugs
Pharmacokinetics at a glance
| Drug | Oral bioavailability | Main elimination | Half-life | Duration (oral) | Food |
|---|---|---|---|---|---|
| Furosemide | About 50% on average (64% tablet, 60% solution) | Mostly unchanged in urine; glucuronide the main metabolite | About 2 h | 6–8 h (IV: onset within 5 min, about 2 h) | Absorption reduced |
| Bumetanide | About 80%; oral ≈ parenteral response | 81% in urine (45% unchanged); side-chain oxidation | 1–1.5 h | 4–6 h | Absorption reduced |
| Torsemide | About 80%; little first-pass | About 80% hepatic (CYP2C9), 20% urine | About 3.5 h | Longest — once daily | No effect on extent |
| Ethacrynic acid | — | — | — | 6–8 h (IV: onset within 5 min) | — |
— = not stated in the listed sources. All loops are highly albumin-bound (furosemide 91–99%, bumetanide 94–96%, torsemide over 99%) and must be secreted into the tubule to act.
Structure and drug-specific points
| Drug | Sulfonamide? | Potency / route notes | Specific point |
|---|---|---|---|
| Furosemide | Yes (sulfamoylanthranilic acid) | IV onset within 5 min | Ototoxicity with rapid injection, renal impairment, high dose, hypoproteinemia or aminoglycosides |
| Bumetanide | Yes (sulfamoylbenzoic acid) | 1 mg ≈ 40 mg furosemide in diuretic potency | Somewhat more chloruretic than natriuretic; give parenterally if gut absorption is impaired |
| Torsemide | Yes (pyridine-sulfonylurea) | Oral ≈ IV (about 80% bioavailable) | CYP2C9 substrate; not dialyzable |
| Ethacrynic acid | No — the non-sulfonamide loop | IV and oral forms | Most ototoxic loop; does not cross the blood–brain barrier |
Cross-allergenicity between sulfonamide antibiotics and sulfonamide diuretics is low, but ethacrynic acid is the safer choice when a sulfonamide allergy is a concern.
Pharmacokinetics
- Absorption
- Furosemide’s oral bioavailability averages about 50% (64% from tablets and 60% from solution relative to IV), while bumetanide and torsemide are about 80% bioavailable — so torsemide’s oral and IV doses are roughly equivalent, unlike furosemide’s. Food leaves torsemide’s overall bioavailability unchanged but reduces furosemide and bumetanide absorption.
- Protein binding and tubular secretion
- Loops are more than 95% albumin-bound (torsemide over 99%), so very little is filtered. They reach their luminal target by active secretion through proximal-tubule organic anion transporters — the same route urate uses, which is why loops raise serum urate and why salicylates compete with furosemide for renal excretion.
- Elimination — furosemide, bumetanide, torsemide
- Furosemide is excreted mostly unchanged in urine (its glucuronide is the main metabolite). Bumetanide is 81% recovered in urine, 45% unchanged, with metabolites from side-chain oxidation. Torsemide is cleared about 80% by hepatic metabolism — mainly CYP2C9, with minor CYP2C8 and CYP2C18 — and 20% in urine.
- Half-life and dosing frequency
- Half-lives are short: about 2 h for furosemide, 1–1.5 h for bumetanide and about 3.5 h for torsemide, which also has the longest duration and suits once-daily dosing. Short-acting loops allow post-diuretic sodium retention as each dose wears off, which is why they are usually given twice daily.
- Onset
- Oral furosemide starts diuresis within 1 hour; IV furosemide and IV ethacrynic acid within about 5 minutes, with the IV furosemide effect peaking within the first half-hour and lasting about 2 hours.
- Organ dysfunction
- In renal failure, torsemide’s renal clearance falls while total clearance does not, so less drug reaches the luminal site and each dose produces less natriuresis. In decompensated heart failure, torsemide’s total clearance is about half normal, but again less reaches the lumen. Hypoproteinemia weakens furosemide’s effect.
- CYP2C9 interactions — torsemide
- CYP2C9 inhibitors (amiodarone, fluconazole, miconazole) raise torsemide levels and inducers (rifampin) lower them; torsemide can in turn affect sensitive CYP2C9 substrates or narrow-therapeutic-index ones such as warfarin and phenytoin.
- Dialysis and distribution
- Hemodialysis does not speed furosemide elimination, and torsemide is not dialyzable. Ethacrynic acid does not cross the blood–brain barrier.
Uses & drug choice
- Edema of heart failure, hepatic cirrhosis, and renal disease/nephrotic syndrome
- Acute pulmonary edema (IV furosemide)
- Hypertension — especially with CKD, where thiazides lose efficacy
- Hypercalcemia — off-label adjunct, only after IV saline volume repletion
Adverse effects
- Hypokalemia and metabolic alkalosis
- Extra distal sodium plus volume depletion activates the RAAS; aldosterone-driven sodium reabsorption leaves the distal lumen negative, trapping K⁺ and H⁺. Loss of sodium-rich, bicarbonate-poor fluid adds a contraction alkalosis.
- Hypocalcemia and hypomagnesemia
- With NKCC2 blocked, ROMK can no longer recycle K⁺ into the lumen, the lumen-positive voltage falls, and the paracellular drive for Ca²⁺ and Mg²⁺ reabsorption is lost.
- Hyponatremia
- Loops lose a great deal of sodium, but because they also abolish the concentrating gradient they cause hyponatremia less often than thiazides, which leave concentrating ability intact.
- Hyperuricemia and gout
- Loops are anions secreted through the organic anion transporters in exchange for urate, so urate is reabsorbed instead. StatPearls lists diagnosed gout as a contraindication to loop and thiazide diuretics.
- Hyperglycemia and lipid changes
- LDL cholesterol and triglycerides can rise, but the mechanism remains unclear; patients with diabetes are at risk of hyperglycemia and need periodic glucose monitoring.
- Ototoxicity
- Loops inhibit NKCC1 in the stria vascularis — the cochlear tissue that secretes endolymph — and cause ischemia there. The damage tracks peak serum levels, so it is most frequent with large IV boluses, and it is usually reversible on stopping. Ethacrynic acid is the most ototoxic loop; renal impairment, hypoproteinemia and aminoglycosides add risk. No other diuretic class shares this effect.
- Volume depletion, hypotension and prerenal azotemia
- This is the potency overshooting (the basis of the boxed warning on furosemide and bumetanide — SPL-coded as a box on furosemide injection and BUMEX, and printed as the opening WARNING block of the LASIX tablet label): excessive diuresis lowers renal blood flow and GFR, causing azotemia, and rapid loss of water and sodium causes orthostatic hypotension or even shock.
- Arrhythmias and digoxin toxicity
- The electrolyte losses — K⁺, Mg²⁺, Ca²⁺ — can provoke serious arrhythmias, and hypokalemia increases digoxin toxicity; among diuretics, loops carry the greatest digoxin-toxicity risk.
Toxicity & antidote
Overdose is the diuretic action taken too far: dehydration, falling blood volume, hypotension and electrolyte imbalance — hypokalemia and hypochloremic alkalosis in particular. Treatment is supportive: replace fluid and electrolytes, correct the acid–base disturbance, and add pressure support if hypotension persists. Hemodialysis does not speed furosemide elimination, and torsemide is not dialyzable.
Interactions
Contraindications
- Anuria — If the kidney makes no urine, a diuretic cannot help and only risks harm — a labeled contraindication.
- Hepatic coma or severe electrolyte depletion (until corrected) — A labeled contraindication — do not start until the condition is improved; sudden fluid/electrolyte shifts can precipitate hepatic coma, and excessive diuresis can cause circulatory collapse.
- Sulfonamide hypersensitivity use caution — Furosemide, bumetanide, and torsemide are sulfonamides; use non-sulfa ethacrynic acid if a true sulfa allergy exists.
- Concurrent aminoglycosides, digoxin, or lithium use caution — Aminoglycosides add ototoxicity, hypokalemia potentiates digoxin toxicity, and loops reduce lithium clearance (toxicity) — monitor closely.
High-yield
- Exception — the only loop without a sulfonamide group
- Ear — the most ototoxic loop
- Escape route — the loop to choose in a serious sulfonamide allergy
Furosemide, bumetanide and torsemide all carry a sulfonamide (sulfamoyl or sulfonylurea) group.
- F — furosemide: about 50% oral bioavailability on average
- B — bumetanide: about 80%; oral and IV responses nearly equal
- T — torsemide: about 80%, plus the longest action (once daily) and CYP2C9 metabolism
Bioavailability is why torsemide’s oral and IV responses are roughly equivalent, while furosemide’s are not.
Practice questions
Q1A 74-year-old man with acute kidney injury and pneumonia is receiving IV gentamicin. To treat fluid overload he is given a large IV bolus of furosemide. An hour later he reports ringing in both ears and muffled hearing.
Which mechanism best explains his new symptoms?
- A.Blockade of NKCC2 in the macula densa, switching off tubuloglomerular feedback
- B.Aldosterone-driven potassium loss in the collecting duct
- C.Inhibition of NKCC1 and ischemia in the cochlear stria vascularis
- D.Blockade of the NaCl cotransporter (NCC) in the distal tubule
- E.Blockade of epithelial sodium channels (ENaC) in the collecting duct
Show answer
C. Inhibition of NKCC1 and ischemia in the cochlear stria vascularis — Loop ototoxicity comes from NKCC1 inhibition and ischemia in the stria vascularis, the cochlear tissue that secretes endolymph. It tracks serum concentration, so large IV boluses — especially in AKI — carry the most risk, and aminoglycosides and renal impairment add to it. It is usually reversible. Macula densa NKCC2 blockade turns off tubuloglomerular feedback, and aldosterone-driven potassium loss causes hypokalemia; neither affects hearing. NCC and ENaC are the thiazide and potassium-sparing targets, and ototoxicity is not shared by any other diuretic class.
Q2A 66-year-old woman with heart failure has been taking furosemide twice daily. Her serum potassium is 2.9 mEq/L and her bicarbonate is 34 mEq/L.
Which mechanism best explains this acid–base and electrolyte pattern?
- A.Increased distal sodium delivery and aldosterone, trapping K⁺ and H⁺ in a lumen-negative distal tubule
- B.Carbonic anhydrase inhibition causing bicarbonate wasting
- C.ENaC blockade suppressing potassium and hydrogen secretion
- D.Loss of ROMK-driven paracellular calcium reabsorption
- E.Free-water retention diluting serum potassium
Show answer
A. Increased distal sodium delivery and aldosterone, trapping K⁺ and H⁺ in a lumen-negative distal tubule — Loops deliver more sodium distally and cause volume depletion, both of which activate the RAAS. Aldosterone drives avid sodium reabsorption, the lumen turns negative, and K⁺ and H⁺ are trapped and lost — hypokalemia with metabolic alkalosis, more common with loops than thiazides, with contraction alkalosis adding to it. Carbonic anhydrase inhibition (acetazolamide) causes metabolic acidosis, and ENaC blockade causes hyperkalemia and acidosis. Losing the lumen-positive voltage explains calcium and magnesium loss, not this pattern. Loops abolish the concentrating gradient rather than promoting free-water retention.
Q3A 9-day-old boy fails to thrive. Labs show hypokalemia, metabolic alkalosis and hypomagnesemia, and renal ultrasound shows nephrocalcinosis. Genetic testing finds a loss-of-function mutation in the same transporter that a common class of diuretics blocks.
Which transporter is affected?
- A.NaCl cotransporter (NCC) of the distal convoluted tubule
- B.Epithelial sodium channel (ENaC) of the collecting duct
- C.Sodium–hydrogen exchanger (NHE3) of the proximal tubule
- D.Aquaporin-2 of the collecting duct
- E.Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) of the thick ascending limb
Show answer
E. Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2) of the thick ascending limb — NKCC2 loss of function causes type I Bartter syndrome, usually present at birth, with hypokalemic metabolic alkalosis, hypomagnesemia and nephrocalcinosis — the picture of a permanent loop diuretic, since losing the lumen-positive voltage lets calcium escape into the urine. Loss of NCC causes Gitelman syndrome, which shares the hypokalemic alkalosis and hypomagnesemia but features hypocalciuria. ENaC blockade causes hyperkalemia. NHE3 works in the proximal tubule, and aquaporin-2 is the vasopressin-regulated water channel of the collecting duct.
Q4A 61-year-old woman with lung cancer has symptomatic hypercalcemia from PTHrP. After she is rehydrated with IV saline, IV furosemide is given to increase calcium excretion.
Why does furosemide increase urinary calcium?
- A.It blocks the NaCl cotransporter, increasing distal calcium reabsorption
- B.It removes the lumen-positive voltage in the thick ascending limb that drives paracellular calcium reabsorption
- C.It inhibits carbonic anhydrase in the proximal tubule
- D.It switches off tubuloglomerular feedback, lowering GFR
- E.It increases calcium reabsorption through the lumen-positive voltage
Show answer
B. It removes the lumen-positive voltage in the thick ascending limb that drives paracellular calcium reabsorption — NKCC2 blockade stops ROMK from recycling potassium into the lumen, so the lumen-positive voltage falls and the paracellular drive for Ca²⁺ (and Mg²⁺) reabsorption is lost — calciuresis. NCC blockade is the thiazide mechanism, and thiazides promote calcium reabsorption. The furosemide label says its distal action is independent of carbonic anhydrase. Tubuloglomerular feedback normally lowers GFR by constricting the afferent arteriole, and loops inhibit it. The lumen-positive voltage is lost, not strengthened.
Q5A 70-year-old woman with a history of Stevens–Johnson syndrome from trimethoprim–sulfamethoxazole develops acute pulmonary edema and needs a potent diuretic.
Which drug avoids a sulfonamide group?
- A.Furosemide
- B.Bumetanide
- C.Torsemide
- D.Ethacrynic acid
- E.Hydrochlorothiazide
Show answer
D. Ethacrynic acid — Ethacrynic acid is the only loop diuretic without a sulfonamide group, which makes it the safer choice when a sulfonamide allergy is a concern. Furosemide (a sulfamoylanthranilic acid), bumetanide (a sulfamoylbenzoic acid) and torsemide (a pyridine-sulfonylurea) all carry one, and thiazides are also sulfonamide derivatives. The trade-off: ethacrynic acid is the most ototoxic loop.
Sources
- Furosemide (Lasix) — indications, electrolyte-depletion warning, digitalis/hypokalemia, sulfa precaution (FDA label) — FDA / DailyMed
- Furosemide injection — ototoxicity warning & ≤4 mg/min infusion rate (FDA label) — FDA / DailyMed
- Loop Diuretics — NKCC2 mechanism, high-ceiling potency, low-GFR efficacy & adverse effects — StatPearls (NCBI)
- Open RN Nursing Pharmacology — Ch. 6 Cardiovascular & Renal (loop diuretics: morning dosing, potassium-rich foods) — Open RN (NCBI Bookshelf)
- LASIX (furosemide) tablets — prescribing information — DailyMed (NLM)
- BUMEX (bumetanide) — prescribing information (boxed warning, contraindications) — DailyMed (NLM)
- EDECRIN (ethacrynic acid) — prescribing information — DailyMed (NLM)
- SOAANZ (torsemide) — DailyMed listing — DailyMed (NLM)
- Drugs@FDA — DEMADEX (NDA 020136) marketing status — U.S. FDA
- Therapeutic Uses of Diuretic Agents — potency, CKD, hypercalcemia, ototoxicity — StatPearls (NCBI)
- Furosemide — indications — StatPearls (NCBI)
- Hyponatremia — medullary gradient; serum sodium — StatPearls (NCBI)
- Hypernatremia — serum sodium above 145 mEq/L — StatPearls (NCBI)
- Physiology, Renal — tubular sodium reabsorption — StatPearls (NCBI)
- Sensorineural Hearing Loss — loop diuretics and the stria vascularis — StatPearls (NCBI)
- Fluid Management — body weight and volume status — StatPearls (NCBI)
- Bumetanide — loop diuretic potency — StatPearls (NCBI)
- The use of stems in the selection of INN (-semide, -etanide) — World Health Organization
- StatPearls: Prerenal Kidney Failure — NCBI Bookshelf (StatPearls)
- StatPearls: Resistant Hypercalcemia — NCBI Bookshelf (StatPearls)
- StatPearls: Physiology, Frank Starling Law — NCBI Bookshelf (StatPearls)
- StatPearls: End-Stage Renal Disease — NCBI Bookshelf (StatPearls)
- Furosemide and the kidney / heart failure — prostaglandin-mediated venodilation (Braz J Med Biol Res 2012, PMC) — Brazilian Journal of Medical and Biological Research (PMC, CC BY-NC 3.0)
- StatPearls: Creatinine Clearance — StatPearls (NCBI)
- Torsemide — pyridine-sulfonylurea, oral ≈ IV bioavailability — StatPearls (NCBI)
- Ethacrynic Acid — non-sulfonamide loop, stria vascularis, excessive diuresis — StatPearls (NCBI)
- Torsemide tablets (Teva) — CYP2C9 metabolism, bioavailability, renal and heart-failure pharmacokinetics (FDA label) — FDA / DailyMed
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.